NASDAQ · Biotechnology

AURA (AURA) Stock

$7.06 -1.40% NASDAQ: AURA Healthcare

Valuation

MetricValue
Price$7.06
Market Cap$453.25M
P/E Ratio-4.35
P/B Ratio3.58
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$9.54
52-Week Low$4.73
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-77.37%
ROA-62.72%
ROCE-83.09%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.16
Current Ratio8.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-35.0M$-60.0M$-85.0M$-96.0M$-113.0M
Net Profit$-35.0M$-59.0M$-76.0M$-87.0M$-106.0M
EPS$-1.58$-1.96$-1.93$-1.75$-1.76
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$160.0M$224.0M$255.0M$183.0M$169.0M
Total Liabilities$8.0M$28.0M$29.0M$31.0M$33.0M
Cash$149.0M$122.0M$41.0M$32.0M$60.0M
Borrowings$1.0M$21.0M$20.0M$19.0M$17.0M

Latest News

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors GlobeNewswire · Jul 8, 2026 Aura Biosciences Completes Enrollment in Phase 3 Trial of Belzupacap Sarotalocan for Early Choroidal Melanoma MT Newswires · Jun 1, 2026 Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma GlobeNewswire · Jun 1, 2026 Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances MarketBeat · May 27, 2026 Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data MarketBeat · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$-55.0M$-64.0M$-80.0M$-85.0M
Investing Cash Flow$-4.0M$-69.0M$-115.0M$68.0M$35.0M
Financing Cash Flow$0$0$2.0M$0$0
Net Cash Flow$132.0M$-27.0M$-81.0M$-9.0M$28.0M
Free Cash Flow$-35.0M$-56.0M$-65.0M$-81.0M$-85.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-18.59%
Quick Ratio7.09
Interest Coverage—
Return 1Y2.86%
Return 3Y-37.98%
Return 5Y—

Ownership

Insiders Held1.16%
Institutions Held49.37%
Institutions Float Held49.95%
Institutional HolderSharesReport Date
Matrix Capital Management Company LP6,922,8702026-03-31
Frazier Life Sciences Management, L.P. 5,100,0002026-03-31
Adage Capital Partners GP L.L.C.4,881,1252026-03-31
Long Focus Capital Management, LLC4,619,5822026-03-31
Suvretta Capital Management, LLC4,372,8842026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
ANNX $5.37 +0.75% -3.71 $879.83M 0.00%
DBVTDBV Technologies S.A. $15.84 +0.83% -3.27 $378.92M 0.00%
DSGN $13.57 +2.80% -11.56 $847.54M 0.00%
ENGN $1.79 +1.70% -0.70 $91.64M 0.00%

About AURA

AURA is led by CEO Elisabet de los Pinos, employs 106 people, headquartered in US, publicly traded since 2021.

AURA stock trades at $7.06 with a market capitalization of $453.25M. The stock is valued at a price-to-earnings (P/E) ratio of -4.35, price-to-book of 3.58, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.73 and $9.54, and currently trades 26.0% below its 52-week high.

On profitability, AURA generates a return on equity (ROE) of -77.37%, return on capital employed of -83.09%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides